The herpes zoster market is predicted to witness a significant rise over the next few years following the launch of two vaccines in major markets. Is this company for real, or did some schmuck create a pipeline and a story out of thin air to dupe me out of my money? Following the formal remarks, we’ll open the call up for your questions. From 1 September, this programme is for the vaccination of patients aged 78 years on 1 September each year. AVAC priorities and objectives are driven by a consensus process with the goal of enabling the range of stakeholders to have a voice in the effort to improve access and utilization of adult immunizations. Malaria may be associated with anemia and jaundice, and may cause kidney failure, coma and death. Transmission routes are becoming increasingly important, as large numbers of people travel globally, giving them the ability to rapidly transmit a disease from one area to another.
5 for people age 65 to 74 and greater than 3 for people age 75 to 84. NanoViricides is a unique biotechnology company focused on nanomedicine and has developed a truly revolutionary, tailorable delivery platform designed to destroy viruses both in and on the body. The numbers have been deteriorating at GSK as franchise drugs lose patent protection and its newer therapies have been slow to catch on. This combination of a chemically attached virus-binding ligand (a mimic of the receptor cell surface protein) derived from the virus’s own binding site with a flexible “nanomicelle” polymer allows nanoviricides to seek out and attach to a specific virus particle in bodily fluids and then fully engulf it, using the polymer as a containment vessel. This process, using targeted, stealth ligands designed to fool the virus into thinking the nanoviricide looks biochemically like a superb infection target, ultimately renders the virus cell incapable of infecting other cells and, subsequently, dismantles it with no collateral damage to healthy cells. EST, during which questions will be answered to aid in the development of proposals. The unique ability of this platform to be used for quickly developing highly optimized, virus-specific drug candidates, which can be tailored for premium pharmacokinetic characteristics, such as sustained effect and diverse routes of administration, is something which grants the company’s nanoviricide technology an enviably disruptive profile.
Investors have rightly focused on the importance of Glaxo’s next-generation respiratory launches, but they’ve completely forgotten that GlaxoSmithKline has a robust pipeline beyond just respiratory. Similarly, data from the 122 Cities Mortality Reporting System for week 6 indicate 6.9% of deaths were due to P&I. 5:e1275. An alarming incident rate increase for Zika of over 2,200 percent in Brazil from 2014 to 2015, with over 3,500 cases last year and 46 infant casualties, has prompted growing concern from health officials worldwide, and with the Florida Department of Health reporting that, as of January 19, two cases of Zika have been identified in Miami-Dade, the three- to five-year window currently proposed by Brazilian authorities for the development of a vaccine (in record time) paints an astoundingly clear picture of the inherent potential value of NNVC’s highly-adaptable platform technology. Transmitted by the same species of mosquito that carries Dengue fever (as well as now being thought to be sexually transmissible), Zika virus, whose symptoms are relatively mild, was initially not considered to be a major threat, even as the number of cases quickly shot up in Brazil. However, an increasingly apparent correlation with birth defects like microcephaly and possibly even the paralytic central nervous system malady, Guillain–Barré syndrome, has turned a lot of heads in the medical community, especially considering the lifelong impairment for children born with such birth defects. NanoViricides’ development pipeline currently boasts a number of promising primary candidates, from an injectable, as well as orally-administered Influenza candidate (FluCide) aimed at the $33 billion plus vaccine market, to indications for HIV/AIDS, and Herpes.
FluCide is quite interesting given the CDC’s own recent acknowledgment that the 2014 to 2015 flu vaccine set record efficacy lows, with a paltry 23 percent reduction to risk of getting the flu. The recent presentation by the CEO of NNVC, Eugene Seymour MD, MPH at Biotech Showcase 2016, illustrated how the company is currently moving full speed ahead with human trials for its lead virucidal herpes (of the eye/cornea) keratitis (inflammation of the cornea) treatment, HerpeCide™. Human clinical trials are currently on-track to begin late this year or in early 2017, and commercially-available HerpeCide would be a most welcome addition to the healthcare system’s existing biomedical arsenal, as ocular herpetic disease in general is a serious challenge for both optometrists and patients. They try to identify the exact protein that is behind a particular ID, and then they use that protein to stimulate our immune system. Looking at viral shedding first because it was the primary end point, the best performing dose of 60 micrograms per protein and 75 micrograms of adjuvant demonstrated a statistically significant 58% reduction in the viral shedding rate six months after dosing. The major herpes viruses that cause ocular disease (simplex and zoster) quite often bring about immunologic reactions in the host that outlive any active infection as well, meaning that the latent demand for a real solution is considerably larger than the baseline market metrics would indicate. There are a variety of topical (as well as oral) treatments available, such as GlaxoSmithKline’s (NYSE: GSK) Viroptic (trifluridine), which carries significant toxicity risk, or Pfizer’s (NYSE: PFE) Vira-A (vidarabine), although it has been largely displaced by Aciclovir, due to the former indication’s administration via IV being cumbersome.
It is estimated that 1 million or more cases occur each year in the United States. NanoViricides recently completed a transition to its new c-GMP-capable, state-of-the-art production and testing facilities in Connecticut, and has thus graduated into a select handful of small biopharma developers with its own in-house, clinical-quality drug manufacturing footprint. With the capacity to see candidates from design through to scaling up of production for IND submissions and human clinical trials, NNVC now also has the muscle to handle commercial-scale manufacturing when (and if) its candidates are eventually licensed. This logistical capacity, combined with the company’s smart weapon nanoviricide platform, means that NNVC’s most advanced candidates, like HerpeCide and FluCide, stand an excellent chance of seeing eventual commercialization. This is great news considering that NNVC’s anti-Herpes candidate has shown such great progress in HSV-1 animal model studies thus far, with an over 85 percent survival rate (compared to zero for untreated animals), as well as a marked ability to reduce virus production in cell cultures. Shown to be superior to topical treatment with an Aciclovir formulation, the company’s HerpeCide candidates could emerge as not only a leading treatment in the space, but a real solution for patients dealing with the disease and potentially facing blindness.